scholarly journals AYURVEDIC PREVENTIVE MEASURES AND POSSIBLE TREATMENT FOR COVID-19

2020 ◽  
Vol p4 (05) ◽  
pp. 2415-2421
Author(s):  
Naringe Seema ◽  
Dighade Shubhangi
Keyword(s):  
Public Health ◽  
Clinical Trials ◽  
Preventive Measures ◽  
Public Health Emergency ◽  
Healthy Individuals ◽  
Ayurvedic Drugs ◽  
Ashtanga Yoga

Ayurveda is the science of life with aim to protect the health of healthy individuals and to cure the diseases of sufferers. Ayurvedic approaches can give fruitful results in prevention and management of COVID19. WHO has declared the outbreak of COVID 19 to be a public health emergency of international concern on 30th January 2020. Ministry of AYUSH, many Ayurveda institutes, eminent Vaidyas give guidelines to combat COVID 19 in preventive and health promotive way. Ayurveda has mentioned Dincharya, Rutu-charya, Sadvrutta Palana, Ashtanga Yoga to prevent any disease. We in this paper tried to show benefits of these Ayurvedic principles in pandemic disease like COVID-19. COVID-19 disease can be correlated with Vatkapha Pradhana Sannipataja Jwara. Many Ayurvedic drugs mainly Ashwagandha, Yashtimadhu, Guduchi are tried for clinical trials for treatment of COVID-19. Clinical trials of Ayurvedic drugs on quar-antine COVID-19 positive patients shows good results with Ayurvedic stand-alone treatment. We in this paper tried to summarize all the possible Ayurvedic approaches in preventive and curative way, clinical trials through Ayurvedic add on and stand-alone treatments. We lastly concluded with positive note that Ayurveda can be beacon of light to fight COVID-19 Pandemic.

Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials

2020 ◽  
Vol 21 ◽  
Author(s):  
Subha Sankar Paul ◽  
Goutam Biswas
Keyword(s):  
Public Health ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Small Molecule ◽  
Mode Of Action ◽  
Antiviral Drugs ◽  
Public Health Emergency ◽  
Advanced Stage ◽  
Clinical Trial Results

: COVID-19 is a public health emergency of international concern. Although, considerable knowledge has been acquired with time about the viral mechanism of infection and mode of replication, yet no specific drugs or vaccines have been discovered against SARS-CoV-2, till date. There are few small molecule antiviral drugs like Remdesivir and Favipiravir which have shown promising results in different advanced stage of clinical trials. Chloroquinine, Hydroxychloroquine, and Lopinavir-Ritonavir combination, although initially was hypothesized to be effective against SARS-CoV-2, are now discontinued from the solidarity clinical trials. This review provides a brief description of their chemical syntheses along with their mode of action and clinical trial results available in Google and different peer reviewed journals till 24th October 2020.

scholarly journals Urgensi Pembentukan Aturan Terkait Pencegahan Covid-19 di Indonesia

2020 ◽  
Vol 12 (01) ◽  
pp. 59-70
Author(s):  
Dalinama Telaumbanua
Keyword(s):  
Public Health ◽  
Infectious Disease ◽  
Infectious Diseases ◽  
Government Regulation ◽  
Preventive Measures ◽  
Public Health Emergency ◽  
Legal Certainty ◽  
Government Regulations ◽  
Contagious Disease ◽  
Health Regulations

Covid-19 is a contagious disease that has the potential to cause a public health emergency. Therefore, preventive measures against these types of infectious diseases are mandatory as soon as possible. Indonesia as a nation of law, the prevention of infectious diseases is mandatory to be formed in a rule or regulation. The urgency of forming rules related to the prevention of Covid-19 is obliged to be formed in government regulation and regulation of the Minister of Health because both regulations are the implementation rules of Law No. 6 of 2018 concerning Health. Based on the author's analysis, there are 5 government regulations that must be established in order to perform countermeasures and prevention of infectious disease threats such as Covid-19 and there are 11 mandatory ministerial health regulations that are required to be established In anticipation of the Covid19 threat. Both types of regulations are very useful in anticipating health emergency that ultimately leads to the health of Indonesian people. It is expected that both of rules can be made immediately in order to give legal certainty in preventing the spread of Covid-19 widely. Keyword: Forming Rules, Management, Covid-19   Abstrak Covid-19 merupakan penyakit menular yang berpotensi menimbulkan kedaruratan kesehatan masyarakat. Oleh sebab itu, tindakan pencegahan terhadap jenis penyakit menular tersebut wajib dilakukan secepat mungkin. Indonesia sebagai negara hukum, maka pencegahan terhadap jenis penyakit menular tersebut wajib dibentuk dalam sebuah aturan atau regulasi. Urgensi pembentukan aturan terkait dengan pencegahan Covid-19 ini wajib dibentuk dalam Peraturan Pemerintah dan Peraturan Menteri Kesehatan karena kedua peraturan tersebut merupakan peraturan pelaksanaan daripada Undang-Undang Nomor 6 Tahun 2018 tentang Kekarantinaan Kesehatan. Berdasarkan analisis penulis, ada 5 Peraturan Pemerintah yang wajib dibentuk dalam rangka melakukan tindakan penanggulangan dan pencegahan ancaman penyakit yang mudah menular seperti Covid-19 dan ada 11 Peraturan Menteri Kesehatan terkait yang wajib dibentuk dalam rangka mengantisipasi ancaman Covid-19. Kedua jenis peraturan tersebut sangat berguna dalam hal mengantisipasi kedaruratan kesehatan yang pada akhirnya menjurus pada kekarantinaan kesehatan masyarakat Indonesia. Kiranya kedua jenis peraturan ini segera dibuat dalam rangka memberi kepastian hukum dalam mencegah menularnya Covid-19 secara meluas. Kata Kunci: Pembentukan Aturan, Penanggulangan, Covid-19

scholarly journals Acute Tuberculosis pneumonia and COVID-19 in a patient vaccinated with Bacille Calmette-Guérin (BCG)

2020 ◽  
Author(s):  
Michelangelo Luciani ◽  
Enrico Bentivegna ◽  
Valerio Spuntarelli ◽  
Ludovica Guerritore ◽  
Dario Chiappino ◽  
...  
Keyword(s):  
Public Health ◽  
Clinical Trials ◽  
Tract Infection ◽  
Preventive Measures ◽  
Multiorgan Failure ◽  
High Rate ◽  
Health It ◽  
Bacille Calmette Guerin ◽  
Acute Distress ◽  
The Right

Abstract COVID-19 is a respiratory tract infection caused by the new coronavirus SARS-COV2, that can be complicated by acute distress respiratory syndrome and multiorgan failure. In light of the high rate of mortality associated with COVID-19, pharmacological and non-pharmacological strategies to prevent the infection are currently being tested. Among non-pharmacological preventive measures, vaccines represent one of the main resources for public health. It has been suggested that Bacille Calmette-Guérin (BCG) vaccine may protect individuals against infection from COVID-19 virus, and two clinical trials addressing this question are underway. Here, we report the case of a 32-year old woman, vaccinated with BCG when she was 1 year old, who was diagnosed with apical tuberculous pneumonia of the right lung along with COVID 19 pneumonia.

scholarly journals Outbreak of COVID-19 pandemic in Pakistan and the current scenario

2020 ◽  
pp. 67-71
Author(s):  
Arslan Habib ◽  
Khalid Mahmood Anjum ◽  
Ajmal Shehzad ◽  
Muhammad Imran ◽  
Zeeshan Ashraf ◽  
...  
Keyword(s):  
Public Health ◽  
Preventive Measures ◽  
Public Health Emergency ◽  
World Health ◽  
Wuhan City ◽  
Government Response ◽  
Current Scenario ◽  
International Issue ◽  
The Government ◽  
Health Organization

The current pandemic of COVID-19 was first observed in the Wuhan city of China in December 2019, which later appeared worldwide. World Health Organization (WHO) declares coronavirus pandemic as an international issue of a public health emergency worldwide. On 11 February 2020, WHO named this virus as Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Different effective preventive measures were implemented to control the transmission of COVID-19. After the COVID-19 pandemic outbreak in Pakistan, the government designed other effective protocols to fight against this zoonotic disease. This review highlighted the COVID-19 outbreak prevalence in Pakistan with their current scenario and the government response to combat the disease.

Die a Hero or Live Long Enough to Become the Villain: Mass Casualty Preparedness in Hospitals and Protecting Doctors from Liability during Mass Casualty Events

2015 ◽  
Vol 6 (1) ◽  
Author(s):  
Ashley Tseung
Keyword(s):  
Public Health ◽  
United States ◽  
Emergency Preparedness ◽  
Preventive Measures ◽  
The United States ◽  
Mass Casualty Incident ◽  
Mass Casualty ◽  
Public Health Emergency ◽  
Terrorist Attacks ◽  
Mass Casualty Events

AbstractSince 9/11, the United States and the international community have emphasized the need to protect people from terrorist attacks. The Boston Bombing that took place on April 15, 2013, showed that even with all of the preventive measures in place, the United States is not immune from terrorist attacks. If there had been a bioterrorist attack in Boston instead of a homemade bomb, the amount of casualties would likely have been a lot higher. Many hospitals lack effective emergency preparedness plans that address bioterrorist attacks. One area that will help prepare nations during a mass casualty incident or public health emergency involves implementing effective mass casualty preparedness plans for hospitals. This paper analyzes mass casualty preparedness in hospitals and demonstrates the need to have legislation in place to protect doctors who treat patients during mass casualty events.

scholarly journals COVID-19 and Rheumatology

2021 ◽  
pp. 6-6
Author(s):  
César Graf
Keyword(s):  
Public Health ◽  
Developing Countries ◽  
Pharmaceutical Industry ◽  
Health Systems ◽  
Preventive Measures ◽  
Public Health Emergency ◽  
World Population ◽  
The World

Since the beginning of the Pandemic, declared by the WHO in January 2020 as a public health emergency, the world population has been submerged in a state of revolution of health, social and geopolitical order, with the pharmaceutical industry and scientists having to prioritize the development of vaccines and governments to experiment with preventive measures aimed at reducing contagion and transmission, in order to strengthen, restructure and reorganize the deficient health systems of developing countries.

Aspects of disaster research ethics applicable to other contexts

2016 ◽  
Vol 44 (1) ◽  
pp. 9-10
Author(s):  
Bridget Haire
Keyword(s):  
Public Health ◽  
Clinical Trials ◽  
Patient Care ◽  
Research Ethics ◽  
Public Health Emergency ◽  
Positive Outcomes ◽  
Disaster Research ◽  
Disadvantaged Populations ◽  
Human Use

In his article ‘The Ebola Clinical Trials: a precedent for research ethics in disasters’, Philippe Calain constructs a compelling case as to why and how experiences from the recent Ebola epidemic should be used to develop a framework for disaster research ethics. In particular, Calain proposes a useful model for assessing whether or not an unproven intervention could be suitable for human use in a disaster context, and makes a powerful argument against the separation of patient care from research goals. In this commentary, I argue that the separation of patient care goals from research goals is also unhelpful in the context of other forms of participant disadvantage even when that disadvantage is less severe than an ongoing public health emergency. I contend that recognising that research in disadvantaged populations is an intervention that could and should aim to produce positive outcomes for participants, just as it should in disaster contexts, therefore seems a well-justified lesson that can be extrapolated from the experience of the Ebola epidemic.

A Review Paper on Pandemic Covid-19

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 994-999
Author(s):  
Swarupa Chakole ◽  
Vaishnavi Jaiswal
Keyword(s):  
Public Health ◽  
Health Care ◽  
High Risk ◽  
Economic Crisis ◽  
Review Paper ◽  
Preventive Measures ◽  
Public Health Emergency ◽  
Clinical Aspects ◽  
Elderly Persons ◽  
Immunocompromised Patients

Covid – 19 national disasters of India declared on 13 March 2020. The word Covid 19-means China originated virus in December 2019.Covid- 19 is emerging disease worldwide and perhaps a pandemic as declared by WHO on 11 March 2020, and came into existence from Wuhan China, Hubei province on 1 December 2019.Covid-19 which not only caused havoc but also lead to an economic crisis because of health care systems.Some advancement in health and its regulations. It has mainly affected elderly persons and immunocompromised patients; pregnant women have not shown more chances of infection until now. Patients mainly present with cough, fever, shortness of breath.patient are categorized as suspected and confirmed cases, high risk and.moderate risk. Here is a discussion on pathology, clinical aspects, gynaecological aspects, forensic aspects, diagnosis, management, prevention. Preventive measures include self-isolation, quarantine, wearing a mask, use of alcohol-based sanitizer and are discussed further. Its management has antiviral therapy, ventilators support. This has set an example of community spread. It is a concern of public health emergency. It has geared up hospitals for an increase in the number of beds, staff and an emergency.

scholarly journals Efforts at COVID-19 Vaccine Development: Challenges and Successes

Vaccines ◽  
2020 ◽  
Vol 8 (4) ◽  
pp. 739 ◽  
Author(s):  
Azizul Haque ◽  
Anudeep B. Pant
Keyword(s):  
Public Health ◽  
Clinical Trials ◽  
Vaccine Development ◽  
Public Health Emergency ◽  
Safety And Efficacy ◽  
Vast Array ◽  
Advantages And Disadvantages ◽  
Rapid Spread ◽  
The World ◽  
The U.S

The rapid spread of SARS-CoV-2, the new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world.

scholarly journals For better response to clinical trials under public health emergency: a descriptive analysis COVID-19, SARS, MERS and Ebola intervention clinical trials registration

2020 ◽  
Author(s):  
Yuxia Xiang ◽  
Zeyu Zhang ◽  
Chan Zeng ◽  
Zhanqing Hu ◽  
Yaxin Liu ◽  
...  
Keyword(s):  
Public Health ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Descriptive Analysis ◽  
Public Health Emergency ◽  
Clinical Trial Registry ◽  
Drug Intervention ◽  
Short Period ◽  
Epidemic Period ◽  
Clinical Trial Program

Abstract BackgroundCOVID-19 is a novel and highly virulent virus, which caused a rapid and massive onset of clinical trials in a short period of time.With the aim to obtain suggestions in the guidance on performing public health emergency clinical trials, and control this virus in China and other countries and for the prevention of the onset of other infectious viruses in the future. Methods COVID-19, SARS, MERS and Ebola clinical trials registered in the Chinese clinical trial registry and clinical trials.gov were collected and analyzed and intervention protocols were descriptively analyzed, focusing on the analysis and comparison of the drug used. The search period ended on February 24, 2020.ResultsThe number of the registered COVID-19 clinical trials was 295. Among 203 intervention trials, 78.3% (159) were drug clinical trials. The 159 COVID-19 trials were designed and analyzed with the highest proportion of random, open control study [66.0% (105)], and blind randomized trials [13.8% (22)]. The drug mostly used was Lopinavir/Ritonavir (15.1%). The sample size median 100,IQR(interquartile range) 140. The number of the registered SARS was 6, MERS 15, and Ebola 97. Among 3 MERS and 19 Ebola drug intervention clinical trials, MERS and Ebola were randomized, blind, and placebo-controlled drug clinical trials accounting for 100% (3) and 31.6% (6), respectively, while SARS were vaccine trials, without drug intervention clinical trials registered.Conclusions Some of the COVID-19 clinical trials and drug selection performed are somewhat disordered, requiring greater attention to the needs, science assumptions, ethics and quality management of the clinical research. Thus, during the epidemic period, the country should deliver guidance on how to perform appropriate emergency clinical trials, design a scientifically based clinical trial program and focus on researching drugs or vaccines that have great potential.

Sign in / Sign up

Export Citation Format

Share Document